추천 제품
생화학적/생리학적 작용
Promotes the growth of IL-2 dependent lymphocytes. Amino acid sequence of IL-2.
포장
One vial contains 10′000 Units
주의사항
Stable at −20 °C; prepare appropriate aliquots and avoid repeated freezing and thawing, since aggregation may occur resulting in apparent loss of activity.
단위 정의
1 U corresponds to the unit activity in the colorimetric MTT-assay with CTLL-2 cells.
물리적 형태
Clear; colorless solution in Dulbecco-PBS; containing 1 mg BSA/mL.
기타 정보
Sales restrictions may apply.
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
이미 열람한 고객
Interleukin 2.
Annual review of immunology, 2, 319-333 (1984-01-01)
Journal of immunology (Baltimore, Md. : 1950), 120(6), 2027-2032 (1978-06-01)
Several soluble factors have recently been associated with the proliferation and differentiation of thymus-derived lymphocytes. One of these factors present in medium conditioned by T cell mitogen-stimulated lymphocytes has the ability to promote the long-term culture of normal and antigen-specific
Proceedings of the National Academy of Sciences of the United States of America, 81(20), 6486-6490 (1984-10-01)
Human interleukin 2 was separated into multiple molecular forms by selective immunoaffinity chromatography and chromatofocusing. For the most part, this heterogeneity was attributed to variations in glycosylation of the threonine residue in position 3 of the polypeptide chain. The various
PloS one, 9(9), e108414-e108414 (2014-10-01)
There are currently no established radiological parameters that predict response to immunotherapy. We hypothesised that multiparametric, longitudinal magnetic resonance imaging (MRI) of physiological parameters and pharmacokinetic models might detect early biological responses to immunotherapy for glioblastoma targeting NG2/CSPG4 with mAb9.2.27
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(15), 1688-1696 (2015-03-25)
The outcome for patients with metastatic or recurrent sarcoma remains poor. Adoptive therapy with tumor-directed T cells is an attractive therapeutic option but has never been evaluated in sarcoma. We conducted a phase I/II clinical study in which patients with
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.